Synvista terminates development of all therapeutic candidates
This article was originally published in Scrip
Executive Summary
Synvista Therapeutics (formally known as Alteon) has terminated all ongoing clinical trials of its product candidates and will focus its resources on maximising the value of its diagnostic assets. The New Jersey-based company also voiced doubts over its ability to continue operating beyond the second quarter of this year, blaming its financial situation and the current economic climate.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.